A pawsitive approach to managing hyperthyroid cats  

Norbrook partnered with Clinician’s Brief and Dr. Susan Little to host a 1-hour race-approved webinar focused on the management of hyperthyroidism in cats using case examples. In this webinar, Dr. Little discusses various treatment options including the benefits and drawbacks of each. Dr. Little also discusses Felanorm® (methimazole) Oral Solution, the first FDA-approved oral methimazole for cats.

Participants will learn:

  • Why hyperthyroidism remains a common endocrine disease in cats

  • How to manage multiple treatment options for feline hyperthyroidism

  • A new oral methimazole solution that will help improve practitioners’ ability to manage hyperthyroidism and reduce reliance on compounded products

Participants will earn CE credit upon completion of the webinar and a short quiz. 

To watch this on-demand webinar, register here: 

Susan Little, DVM, DABVP (Feline Practice), is part owner of two feline specialty practices in Ottawa, Canada. She earned her DVM from University of Guelph and has served on the board of the International Council for Veterinary Assessment, the American Association of Feline Practitioners, and the Winn Feline Foundation. She is a peer reviewer for veterinary journals and author of several books including: The Cat: Clinical Medicine and Management, St. Louis, Elsevier Saunders, 1st ed, 2012 and 2nd ed, 2024: editor and author and August's Consultations in Feline Internal Medicine, Volume 7, St. Louis, Elsevier Saunders, 2015: editor and author. 

Dr. Little was also the recipient of the Canadian Veterinary Medical Association Small Animal Practitioner Award, the NAVC Small Animal Speaker of the Year Award, and the International Society of Feline Medicine/Hill's Pet Nutrition Award for outstanding contributions to feline medicine.

IMPORTANT SAFETY INFORMATION:

CAUTION: As with all drugs, side effects may occur. The most commonly reported side effects are anorexia, vomiting, head/facial pruritus or edema, depression/lethargy, weight loss, anemia, elevated liver enzymes, skin lesions, elevated BUN, diarrhea, and thrombocytopenia. Felanorm® Oral Solution is not for use in pregnant or lactating queens, or cats with renal, hepactic, or hematological disorders. In some reported cases, the patients recovered after adverse signs were recognized, the drug was withdrawn, and veterinary care was applied. In some cases, death (or euthanasia) has been reported as an outcome of the adverse reactions listed above. Methimazole has anti-vitamin K activity and may induce bleeding diathesis without evidence of thrombocytopenia. Refer to the prescribing information here for complete details.